Automate Your Wheel Strategy on NVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including NVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVAX
- Rev/Share 6.658
- Book/Share 0.2322
- PB 37.3343
- Debt/Equity 6.0728
- CurrentRatio 2.3629
- ROIC 0.3662
- MktCap 1408195662.0
- FreeCF/Share -3.9218
- PFCF -2.2162
- PE 3.3222
- Debt/Assets 0.171
- DivYield 0
- ROE -1.4233
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVAX | H.C. Wainwright | -- | Buy | -- | $10 | Aug. 28, 2025 |
| Downgrade | NVAX | BofA Securities | Neutral | Underperform | -- | $7 | Aug. 20, 2025 |
| Initiation | NVAX | Citigroup | -- | Sell | -- | $6 | June 17, 2025 |
| Initiation | NVAX | BTIG Research | -- | Buy | -- | $19 | Feb. 28, 2025 |
News
Novavax (NVAX) Outperforms Broader Market: What You Need to Know
NVAX
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.
Read More
About Novavax, Inc. (NVAX)
- IPO Date 1995-12-05
- Website https://www.novavax.com
- Industry Biotechnology
- CEO John Charles Jacobs
- Employees 952
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.